Merck’s Saphris Gets FDA Letter After Taking Informant To Lunch
This article was originally published in The Pink Sheet Daily
Executive Summary
A complaint to the “Bad Ad” program that a speaker had promoted an unapproved use for Merck’s atypical antipsychotic Saphris leads FDA’s Office of Prescription Drug Promotion to issue a “notice of violation” letter.